118 related articles for article (PubMed ID: 35734083)
1. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Sand IK; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F
medRxiv; 2022 Jun; ():. PubMed ID: 35734083
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Katz Sand I; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F
Mult Scler Relat Disord; 2023 Feb; 70():104486. PubMed ID: 36628884
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
4. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
5. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
6. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
7. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
[TBL] [Abstract][Full Text] [Related]
8. Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders.
Algu P; Hameed N; DeAngelis T; Stern J; Harel A
Mult Scler Relat Disord; 2023 Nov; 79():104965. PubMed ID: 37657307
[TBL] [Abstract][Full Text] [Related]
9. Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
Woopen C; Konofalska U; Akgün K; Ziemssen T
Front Immunol; 2022; 13():897748. PubMed ID: 35958567
[TBL] [Abstract][Full Text] [Related]
10. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab.
Madelon N; Heikkilä N; Sabater Royo I; Fontannaz P; Breville G; Lauper K; Goldstein R; Grifoni A; Sette A; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
JAMA Neurol; 2022 Apr; 79(4):399-404. PubMed ID: 35212717
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.
Laquintana V; Mottini C; Marchesi F; Marcozzi B; Terrenato I; Sperandio E; de Latouliere L; Carrieri F; Pimpinelli F; Pontone M; Pellini R; Campo F; Conti L; Accetta C; Mandoj C; Petrone F; Di Bella O; Vujovic B; Morrone A; Compagnone M; Principato E; Pinto E; Papa E; Falcucci P; La Malfa A; Pallocca M; De Marco F; Piaggio G; Ciliberto G; Mengarelli A; di Martino S
Front Immunol; 2023; 14():1221587. PubMed ID: 38343436
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
van Kempen ZLE; Stalman EW; Steenhuis M; Kummer LYL; van Dam KPJ; Wilbrink MF; Ten Brinke A; van Ham SM; Kuijpers T; Rispens T; Eftimov F; Wieske L; Killestein J;
J Neurol Neurosurg Psychiatry; 2023 Apr; 94(4):280-283. PubMed ID: 36564175
[TBL] [Abstract][Full Text] [Related]
13. The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans.
Frankel AE; Capozzola T; Andrabi R; Ahn C; Zhou P; He WT; Burton DR
Med Res Arch; 2022 Jul; 10(7):. PubMed ID: 36405515
[TBL] [Abstract][Full Text] [Related]
14. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Rescigno M; Agrati C; Salvarani C; Giannarelli D; Costantini M; Mantovani A; Massafra R; Zinzani PL; Morrone A; Notari S; Matusali G; Pinter GL; Uccelli A; Ciliberto G; Baldanti F; Locatelli F; Silvestris N; Sinno V; Turola E; Lupo-Stanghellini MT; Apolone G;
Front Immunol; 2023; 14():1104124. PubMed ID: 36776853
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year.
Disanto G; Galante A; Cantu' M; Sacco R; Mele F; Eisler JJ; Keller F; Bernasconi E; Sallusto F; Zecca C; Gobbi C
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36396447
[TBL] [Abstract][Full Text] [Related]
17. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
18. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
[TBL] [Abstract][Full Text] [Related]
19. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
[TBL] [Abstract][Full Text] [Related]
20. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.
Wieske L; van Dam KPJ; Steenhuis M; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Kuijpers TW; Rispens T; Eftimov F;
Lancet Rheumatol; 2022 May; 4(5):e338-e350. PubMed ID: 35317410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
